Zealand Pharma A/S (ZEAL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZEAL POWR Grades
- ZEAL scores best on the Growth dimension, with a Growth rank ahead of 0% of US stocks.
- The strongest trend for ZEAL is in Growth, which has been heading down over the past 117 days.
- ZEAL ranks lowest in Growth; there it ranks in the 0th percentile.
ZEAL Stock Summary
- Of note is the ratio of Zealand Pharma A's sales and general administrative expense to its total operating expenses; only 0.44% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for Zealand Pharma A is higher than it is for about just 0.53% of US stocks.
- With a year-over-year growth in debt of -100%, Zealand Pharma A's debt growth rate surpasses merely 0% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Zealand Pharma A are ATIF, PATI, BOMN, PFIE, and AC.
- Visit ZEAL's SEC page to see the company's official filings. To visit the company's web site, go to www.zealandpharma.com.
ZEAL Stock Price Chart Interactive Chart >
ZEAL Price/Volume Stats
| Current price | $29.10 | 52-week high | $44.42 |
| Prev. close | $29.14 | 52-week low | $27.90 |
| Day low | $29.10 | Volume | 2,132 |
| Day high | $30.39 | Avg. volume | 14,900 |
| 50-day MA | $30.09 | Dividend yield | N/A |
| 200-day MA | $33.71 | Market Cap | 1.27B |
Zealand Pharma A/S (ZEAL) Company Bio
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.
Latest ZEAL News From Around the Web
Below are the latest news stories about Zealand Pharma A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.
Zealand Pharma A/S – Final Transactions Under Share Repurchase ProgramCompany announcement – No. 47 / 2021 Zealand Pharma A/S – Final Transactions Under Share Repurchase Program Copenhagen, DK, 27 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. Zealand has entered an arrangeme |
Zealand Pharma A/S – Transaction Under Share Repurchase ProgramCompany announcement – No. 47 / 2021 Zealand Pharma A/S – Transaction Under Share Repurchase Program Copenhagen, DK and Boston, MA, 20 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. Zealand has entered an a |
ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAMCompany announcement No. 45 / 202 1 |
Total number of shares and voting rights in Zealand Pharma at June 30, 2021Company announcement – No. 44/ 2021 Total number of shares and voting rights in Zealand Pharma at June 30, 2021 Copenhagen, DK and Boston, MA, June 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of |
Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)Company announcement – No. 43/ 2021 Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA) Company to present three posters, including two on glepaglutide for the treatment of Short Bowel Syndrome (SBS)Data demonstrate potential dosing benefits of glepaglutide for patients with SBS Copenhagen, DK and Boston, MA, U.S. June 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company f |
ZEAL Price Returns
| 1-mo | -2.87% |
| 3-mo | -11.82% |
| 6-mo | -8.72% |
| 1-year | -17.53% |
| 3-year | 102.79% |
| 5-year | N/A |
| YTD | -19.03% |
| 2020 | 8.25% |
| 2019 | 185.96% |
| 2018 | -14.63% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching ZEAL
Want to do more research on Zealand Pharma A's stock and its price? Try the links below:Zealand Pharma A (ZEAL) Stock Price | Nasdaq
Zealand Pharma A (ZEAL) Stock Quote, History and News - Yahoo Finance
Zealand Pharma A (ZEAL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...